TickerFacts.

Genprex, Inc. (GNPX): Cash & Equivalents

Annual figures by period end, from SEC filings.

$7.83M
As of 2025-12-31
$15.15M
As of 2026-06-30
-28.0%
3-year compound annual growth
$20.95M2016-12-31: $1.60M2017-12-31: $161.3K2022-12-31: $20.95M2023-12-31: $6.74M2024-12-31: $1.60M2025-12-31: $7.83M$7.83M
2016-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$7.83M+388.9%2026-03-30, Balance as of period end
2024-12-31$1.60M-76.2%2026-03-30, Balance as of period end
2023-12-31$6.74M-67.8%2025-04-01, Balance as of period end
2022-12-31$20.95Mn/a2024-04-01, Balance as of period end
No annual figure between 2017-12-31 and 2022-12-31.
2017-12-31$161.3K-89.9%2018-04-17, Balance as of period end
2016-12-31$1.60Mn/a2018-04-17, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Genprex, Inc. (GNPX)2025-12-31$7.83M+388.9%
Oragenics Inc (OGEN)2025-12-31$4.40M+408.7%
Medicus Pharma Ltd. (MDCX)2025-12-31$8.71M+109.0%
Longeveron Inc. (LGVN)2025-12-31$4.66M-75.8%
Korsana Biosciences, Inc. (KRSA)2025-12-31$3.24M+0.2%
Lunai Bioworks Inc. (LNAI)2026-06-30$1.71Mn/m
Nanoviricides, Inc. (NNVC)2026-06-30$2.79M+79.3%
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)2025-12-31$334.0K-82.6%
Cocrystal Pharma, Inc. (COCP)2025-12-31$7.03M-28.8%

Compare GNPX, OGEN, MDCX, LGVN side by side · Screen every company in Pharmaceutical Preparations ↗